article thumbnail

How long should immune checkpoint inhibitor therapy be used in non-small cell lung cancer?

Hospital Pharmacy Europe

Immune checkpoint inhibitors have transformed the management of non-small cell lung cancer, but how long should treatment be continued for optimal survival? It has long been recognised that a hallmark of cancer is immune evasion and that the immune system is held back by inhibitory immune checkpoint receptors and ligands.

article thumbnail

Evernorth: Use of ICI therapies to treat cancer is growing. Here's what payers need to know

Fierce Healthcare

The number of cancer patients using immune checkpoint inhibitor drugs has steadily risen since they hit the market in 2011, and a new report from Evernorth offers payers key strategies to manage th | The number of cancer patients using immune checkpoint inhibitor drugs has steadily risen since they hit the market in 2011, and a new report from Evernorth (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What to eat when you have a sore throat

The Checkup by Singlecare

While there’s no sore throat “diet” per se, eating to support your immunity is essential—before, during, and after an illness. A well-balanced diet rich in fruits and vegetables helps keep your immune system strong, which can help prevent you from catching a cold or flu. What food is good for a sore throat?

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Verily’s Immune Profiler can, Kim asserted, “generate more than 8 million immune measures across 24 immune cell subsets”.

article thumbnail

Early cell therapy successes start to turn the tide in lupus

Pharmaceutical Technology

In August 2021, Saphnelo, a type 1 interferon receptor antibody, became the first lupus treatment to be approved since GSK’s Benlyta (belimumab) won a regulatory nod in 2011. In lupus, the body’s immune system starts to attack its own cells. As per AstraZeneca's recent Q3 earnings, Saphnelo has yielded $69 million to date this year.

article thumbnail

BMS swoops on Forbius, snaring another immuno-oncology player

pharmaphorum

Since its foundation in 2011, privately-held Forbius has been working on drugs that inhibit TGF beta 1 and 3, two targets thought to play a role in protecting cancers from attack by the immune system and the development of fibrosis (scarring).

article thumbnail

BMS’ Orencia gets FDA nod for GvHD thanks to real-world data

pharmaphorum

Orencia (abatacept) becomes the first drug to be approved to prevent GvHD , a condition in which donor immune cells attack tissues in the patient receiving an HSCT, commonly known as a bone marrow transplant. billion in the first nine months of the year.

FDA 100